cannabis stocks

Tilray stock surged then fell on marijuana rescheduling news. Schedule III change eases taxes but won't unlock U.S. market entry without full legalization.

Analyst Keith Speights predicts $GTI will double within three years, citing strong fundamentals and growth catalysts despite 41x forward earnings valuation.

Green Thumb stock fell 10% YTD despite analyst targets doubling current prices. A licensing deal shift to $70M fixed annual fee could significantly boost earnings as revenue expands.

Canopy Growth collapsed 99.6% due to persistent losses, regulatory barriers, and cash burn. Analyst recommend stronger alternatives like Green Thumb Industries.

Tilray posts record $217.5M quarterly revenue and narrows losses, but persistent negative cash flow and competitive headwinds keep investors wary.

Altria's proven profitability and 6.1% dividend outshine Tilray's persistent losses and shareholder dilution in cannabis sector comparison.

Aurora Cannabis stock down 96% since 2021. Despite cannabis reclassification benefits, the company faces headwinds from weak revenue, losses, and exited U.S. operations.

Tilray struggles with profitability despite diversification into hemp and beverages. Acquisition-driven growth caused shareholder dilution and asset write-downs, raising questions about long-term viability.

Tilray and Canopy Growth strengthen positions amid shifting U.S. cannabis regulations. Both improve financials, with Tilray offering broader geographic diversification versus Canopy's focused approach.